Nmo Spectrum

Disclaimer: This information is intended for educational purposes only and does not constitute medical advice. Clinical decisions must always be based on the individual patient's condition, the clinician's judgment, and current medical evidence. Always consult with a qualified healthcare professional.

Overview

• Definition: Neuromyelitis Optica Spectrum Disorder (NMOSD) is a severe, relapsing, inflammatory demyelinating disease of the central nervous system (CNS) that predominantly affects the optic nerves and spinal cord. It is distinct from multiple sclerosis (MS) and is characterized in most cases by the presence of autoantibodies against aquaporin-4 (AQP4-IgG). In a smaller subset of patients, autoantibodies against Myelin Oligodendrocyte Glycoprotein (MOG-IgG) are found, which is now increasingly considered a separate disease entity (MOG-associated disease, MOGAD).
• Epidemiology:
  • Prevalence: Estimated at 0.5 to 10 per 100,000 population worldwide, with potential variations based on ethnicity (higher prevalence in non-Caucasian populations).
  • Incidence: Approximately 0.05 to 0.4 per 100,000 person-years.
  • Sex: Predominantly affects women, with a female-to-male ratio of 3-9:1, particularly in AQP4-IgG positive cases. This ratio is closer to 1:1 in AQP4-IgG negative or MOGAD cases.
  • Age of Onset: Bimodal distribution, with peaks in childhood/adolescence and in middle age (30s-40s). It can occur at any age.
  • Ethnicity: Higher prevalence and severity observed in individuals of African, East Asian, and South Asian descent compared to Caucasians.
• Classification:
  • AQP4-IgG-positive NMOSD: The most common and well-characterized form, defined by the presence of antibodies against AQP4.
  • AQP4-IgG-negative NMOSD: Patients presenting with typical NMOSD clinical features but lacking detectable AQP4-IgG. This group is often further investigated for MOG-IgG.
  • MOG-associated disease (MOGAD): Increasingly recognized as a distinct inflammatory demyelinating disease, characterized by antibodies against MOG. While sharing some phenotypic overlap with NMOSD and MS, it has distinct clinical, radiological, and prognostic features. Some international consensus panels still include MOGAD as a subtype of NMOSD, while others classify it separately. This document will focus primarily on AQP4-IgG positive NMOSD, but acknowledges the close differential with MOGAD.

Pathophysiology

• Mechanism:
  • AQP4-IgG mediated: In AQP4-IgG positive NMOSD, autoantibodies against aquaporin-4, a water channel protein highly expressed on astrocytic foot processes, play a central role. AQP4-IgG is typically of the IgG1 subclass and activates the classical complement pathway.
  • Astrocytopathy: AQP4-IgG binds to AQP4 on astrocytes, leading to astrocyte injury and death. This astrocytic damage is the primary pathogenetic event, distinguishing NMOSD from MS (which is primarily an oligodendrocytopathy).
  • Secondary Demyelination and Neuronal Damage: Astrocytic damage leads to breakdown of the blood-brain barrier, influx of inflammatory cells (neutrophils, eosinophils, macrophages, T cells), complement activation, and subsequent oligodendrocyte injury and demyelination, as well as potential neuronal loss.
  • Lesion Pathology: Characterized by necrotizing inflammation with loss of AQP4 expression, complement deposition, demyelination, and often vasculocentric distribution of inflammation.
• Risk Factors:
  • Genetic Predisposition: Certain HLA haplotypes (e.g., HLA-DRB1*03:01) have been associated with increased risk, though the genetic contribution is less pronounced than in MS.
  • Environmental Factors: No definitive environmental triggers have been identified, unlike MS.
  • Autoimmune Comorbidities: Higher prevalence of other autoimmune diseases (e.g., Sjögren's syndrome, systemic lupus erythematosus, myasthenia gravis, thyroiditis) in NMOSD patients, suggesting a broader autoimmune diathesis.
• Protective Factors: None definitively identified.

Clinical Presentation

Signs and Symptoms

• Cardinal Features: Attacks are typically severe, leading to significant disability.
  • Optic Neuritis (ON): Unilateral or bilateral, severe, often painful vision loss. Can be recurrent. Vision loss is usually more severe than in MS, with involvement of more than half of the optic disc (chiasmal involvement) or extending posteriorly.
  • Acute Myelitis (TM): Severe, longitudinally extensive transverse myelitis (LETM), typically extending over ≥3 vertebral segments. Presents with motor weakness (paraparesis/quadriparesis), sensory deficits (numbness, paresthesias, pain, Lhermitte's sign), and bladder/bowel dysfunction (urinary retention, incontinence).
  • Area Postrema Syndrome: Attacks involving the area postrema in the brainstem, leading to intractable hiccups and/or nausea/vomiting. Highly suggestive of NMOSD.
  • Acute Brainstem Syndrome: Symptoms related to brainstem lesions (e.g., diplopia, dysphagia, facial numbness, vertigo, ataxia).
  • Symptomatic Cerebral Syndrome: Episodes related to large cerebral lesions, which can present as narcolepsy, encephalopathy, symptomatic hydrocephalus, or cognitive impairment.
  • Diencephalic Syndrome: Endocrine disturbances (e.g., SIADH, diabetes insipidus, hyperprolactinemia) or narcolepsy due to hypothalamic involvement.
• Early Signs: Typically, the first attack involves either ON or TM, often leading to rapid and significant disability within days to weeks. Area postrema syndrome can be an early and striking symptom.
• Advanced Signs: Accumulation of disability from recurrent severe attacks affecting different CNS regions. Severe visual impairment or blindness, paraplegia, chronic neuropathic pain, bladder/bowel dysfunction, and respiratory failure (due to high cervical myelitis) are common long-term sequelae.
• Atypical Presentations:
  • Acute encephalitis (rare, but can occur with extensive cerebral lesions).
  • Sudden unexplained death (extremely rare, possibly due to brainstem involvement affecting vital centers).
  • Lesions limited to specific locations (e.g., isolated recurrent optic neuritis without myelitis).

Physical Examination

• Inspection:
  • Observation of gait for ataxia or spasticity.
  • Assessment of general neurological status, signs of distress.
• Palpation: Not typically yield specific findings in NMOSD.
• Special Tests:
  • Ophthalmological Exam: Visual acuity (Snellen chart), color vision (Ishihara plates), fundoscopy (optic disc swelling in acute ON, pallor in chronic ON), visual field testing (perimetry).
  • Neurological Examination:
    • Motor: Strength assessment (MRC scale), tone (spasticity), reflexes (hyperreflexia, clonus), Babinski sign.
    • Sensory: Pinprick, light touch, proprioception, vibration sense (sensory level).
    • Cranial Nerves: Especially III, IV, VI for ocular motility (diplopia), VII for facial weakness, IX, X for dysphagia, XII for tongue weakness.
    • Coordination: Finger-to-nose, heel-to-shin test for ataxia.
    • Autonomic: Assessment of bladder fullness on palpation, bowel sounds, orthostatic hypotension.

Diagnostic Approach

History Taking

• Key Questions:
  • Detailed history of neurological symptoms: onset, severity, progression, exact nature (e.g., "blurriness" vs. "complete loss of vision" with ON, level of weakness with myelitis).
  • History of previous similar episodes, duration, recovery between episodes.
  • Presence of pain (eye pain with ON, neuropathic pain with myelitis).
  • Bladder/bowel dysfunction, sexual dysfunction.
  • Symptoms suggestive of area postrema involvement (intractable hiccups, nausea/vomiting).
  • Any concurrent autoimmune diseases or family history of autoimmunity.
  • Recent infections or vaccinations (rarely implicated as triggers).
  • Drug history.
• Red Flags:
  • Rapidly progressive severe vision loss or weakness.
  • Symptoms of brainstem involvement (e.g., diplopia, dysphagia, intractable hiccups).
  • Acute bladder/bowel retention.
  • Respiratory distress (suggestive of high cervical myelitis).

Laboratory Tests

• First-Line:
  • AQP4-IgG Serology: Most crucial diagnostic test. Performed using highly sensitive and specific cell-based assays (CBA). ELISA and immunofluorescence are less sensitive and specific and generally not recommended.
    • Positive AQP4-IgG (CBA): Supports the diagnosis of NMOSD if clinical criteria are met.
    • Negative AQP4-IgG: Does not rule out NMOSD; consider retesting later, or testing for MOG-IgG.
  • Basic blood tests: CBC, electrolytes, LFTs, renal function, ESR, CRP to rule out systemic inflammation or infection.
  • Vitamin B12, folate: To rule out nutritional myelopathy.
  • ANA, anti-dsDNA, ENA panel, anti-Ro/La, RF, anti-thyroid antibodies: To screen for associated autoimmune diseases.
  • Syphilis and HIV serology: To rule out infectious etiologies.
• Confirmatory:
  • Cerebrospinal Fluid (CSF) Analysis:
    • Often shows pleocytosis (lymphocytic or neutrophilic) during acute attacks, sometimes with a very high white cell count (>50 cells/mm³ is more common than in MS).
    • Protein may be elevated.
    • Oligoclonal bands (OCBs): Typically absent or transient in NMOSD (<20% of patients), which helps differentiate from MS where OCBs are present in >90% of cases.
    • AQP4-IgG levels in CSF are typically lower or undetectable compared to serum.
  • MOG-IgG Serology: If AQP4-IgG is negative, particularly in patients with recurrent optic neuritis, specific brainstem syndromes, or extensive myelitis with conical cord lesions.
• Monitoring:
  • AQP4-IgG titers: Not routinely recommended for activity monitoring as they don't consistently correlate with disease activity or relapse risk.
  • General health monitoring: Regular blood tests to monitor for side effects of immunosuppressive therapies (e.g., CBC, LFTs, renal function).

Imaging

• Recommended (Acute Attack):
  • Brain MRI with gadolinium (contrast):
    • Normal brain MRI: Common in NMOSD patients, especially early in the disease course, which helps distinguish from MS.
    • Typical lesions (minority of patients):
      • Periependymal lesions around the third and fourth ventricles, notably in the area postrema (dorsal medulla) or hypothalamus, thalamus, or brainstem.
      • Large, tumefactive, or enhancing cortical/subcortical lesions.
      • Optic nerve involvement: T2 hyperintensity and contrast enhancement (often longitudinally extensive, involving >50% of the optic nerve length or extending to the optic chiasm).
    • MS-like lesions: Should raise suspicion for MS, not NMOSD.
  • Spinal Cord MRI with gadolinium (contrast):
    • Longitudinally Extensive Transverse Myelitis (LETM): T2 hyperintense lesion extending over ≥3 vertebral segments. This is a highly characteristic feature of NMOSD.
    • Often centrally located within the cord, with associated cord swelling and heterogeneous enhancement during acute attacks.
• Advanced (Chronic/Monitoring):
  • Optical Coherence Tomography (OCT): Used to measure retinal nerve fiber layer (RNFL) and ganglion cell layer (GCL) thickness. Significant thinning indicates previous optic neuritis and can be used to monitor neuroaxonal damage and disease progression in the optic nerves.
  • Visual Evoked Potentials (VEP): Can show prolonged latencies, indicative of demyelination in the optic pathways, even if visual acuity is preserved.

Management

Acute Management

• Immediate:
  • High-dose intravenous corticosteroids: First-line treatment for acute attacks.
    • Methylprednisolone 1000 mg IV once daily for 3-5 days.
    • Followed by an oral corticosteroid taper (e.g., prednisone) for several weeks to prevent rebound inflammation.
• Stabilization:
  • Plasma Exchange (PLEX) / Therapeutic Plasma Apheresis (TPE): For patients who do not respond adequately to high-dose corticosteroids or for severe attacks.
    • Usually 5-7 exchanges performed over 7-14 days. The earlier PLEX is initiated (within days of steroid failure), the better the outcomes.
    • Current evidence supports PLEX for severe acute attacks regardless of AQP4-IgG status.
• Emergency:
  • Respiratory support: In cases of severe high cervical myelitis causing respiratory muscle weakness (diaphragmatic paralysis). May require mechanical ventilation.
  • Bladder catheterization: For acute urinary retention.
  • Pain management: High-dose opioids for severe acute neuropathic pain, while underlying inflammation is treated.

Chronic Management (Prevention of Relapses)

• Pharmacological: Lifelong immunosuppression is typically required for AQP4-IgG positive NMOSD due to the high relapse rate and potential for severe, irreversible disability.
  • First-Line Prophylaxis:
    • Rituximab: Anti-CD20 monoclonal antibody.
      • Dosing: 1000 mg IV every 6 months (preferred due to less frequent administration) OR 375 mg/m² weekly for 4 weeks, then maintenance every 6-12 months. Some protocols use 500 mg IV every 6 months.
      • Mechanism: Depletes B-cells, which are involved in AQP4-IgG production.
      • Monitoring: CD19/CD20 lymphocyte count (aim for depletion), IgG levels (can cause hypogammaglobulinemia). Co-administer with corticosteroids for the first few doses to reduce infusion reactions.
    • Eculizumab: Terminal complement inhibitor. Approved specifically for AQP4-IgG positive NMOSD.
      • Dosing: Initial phase: 900 mg IV weekly for 4 doses, then maintenance: 1200 mg IV every 2 weeks.
      • Mechanism: Blocks C5, preventing complement-mediated damage.
      • Monitoring: Mandatory meningococcal vaccination (ACWY and B) at least 2 weeks prior to starting eculizumab due to increased risk of Neisseria meningitidis infection. Monitor LFTs, renal function.
    • Satralizumab: IL-6 receptor antagonist. Approved for AQP4-IgG positive NMOSD.
      • Dosing: SC injection: 120 mg at weeks 0, 2, and 4, then every 4 weeks.
      • Mechanism: Inhibits IL-6 signaling, which plays a role in B-cell activation and pathogenic antibody production.
      • Monitoring: Liver enzymes, CBC, lipids. Ensure vaccinations are up-to-date.
    • Inazumab (inebilizumab): Anti-CD19 monoclonal antibody. Approved for AQP4-IgG positive NMOSD.
      • Dosing: IV infusion 300 mg at Day 1 and Day 15, then every 6 months.
      • Mechanism: Leads to broad B-cell depletion, including plasmablasts.
      • Monitoring: Lymphocyte counts, IgG levels.
  • Traditional Immunosuppressants (often used off-label where newer agents are unavailable or as add-on therapy):
    • Azathioprine:
      • Dosing: 2-3 mg/kg/day orally (target dose 150-250 mg/day). Onset of action is slow (3-6 months).
      • Monitoring: CBC (leukopenia, anemia, thrombocytopenia), LFTs. TPMT enzyme assay prior to initiation to guide dosing and reduce myelosuppression risk.
    • Mycophenolate Mofetil (MMF):
      • Dosing: 1000-1500 mg orally twice daily.
      • Monitoring: CBC, LFTs.
    • Corticosteroids (low-dose oral prednisone):
      • Dosing: 5-10 mg daily or on alternate days, often used as bridging therapy until other agents take effect, or as an add-on in stubborn cases.
      • Side effects: Long-term risk of osteoporosis, diabetes, hypertension, weight gain.
• Non-pharmacological:
  • Rehabilitation: Physical therapy, occupational therapy, speech therapy for motor, sensory, balance, and swallowing deficits. Crucial for maximizing functional independence.
  • Pain management: Neuropathic pain is common; often requires gabapentin, pregabalin, tricyclic antidepressants, or SNRIs.
  • Bladder/Bowel management: Regular toileting, catheterization as needed, laxatives, dietary modifications.
  • Psychological support: Counseling for depression, anxiety, and coping with chronic illness.
  • Lifestyle: Healthy diet, regular exercise (as tolerated), smoking cessation.
• Monitoring:
  • Clinical monitoring: Regular neurological examinations, visual acuity testing, assessment of functional status and relapse frequency.
  • MRI: Not routinely recommended for monitoring disease activity in quiescent NMOSD outside of clinical trials, as lesions often don't enhance. However, new symptoms should warrant an MRI.
  • OPD (Optic Disc Photography) / OCT: Annually or biannually to monitor for progressive optic nerve atrophy or GCL thinning.
  • Immunosuppressant drug monitoring: As detailed above (e.g., CBC, LFTs for azathioprine/MMF, IgG levels for rituximab/inebilizumab, meningococcal vaccination for eculizumab).

Treatment Algorithms

• First-Line (for AQP4-IgG positive NMOSD):
  1. Acute Attack: High-dose IV Methylprednisolone (1g/day for 3-5 days).
  2. If inadequate response/severe attack: Plasma Exchange (PLEX) 5-7 sessions.
  3. Relapse Prevention: Start a highly effective long-term immunosuppressant. Recommended options include eculizumab, inebilizumab, satralizumab (all approved for AQP4-IgG+ NMOSD), or rituximab (off-label but widely used). Oral immunosuppressants like azathioprine or mycophenolate mofetil are often considered second-line or in resource-limited settings.
• Second-Line (for AQP4-IgG positive NMOSD):
  • If a patient fails to respond to or experiences breakthrough disease on a first-line agent, switch to another first-line agent from a different mechanistic class (e.g., if on rituximab, consider eculizumab or satralizumab).
  • Combination therapy with two different immunosuppressants may be considered in highly active disease, though evidence is limited.
• Refractory Cases:
  • Consider more intensive immunosuppression, such as cyclophosphamide (monthly IV pulses).
  • Trial other approved agents not yet used.
  • Consider enrollment in clinical trials for novel therapies.
  • Re-evaluate diagnosis carefully, especially for atypical presentations or if MOG-IgG status was not checked.

Complications

• Common:
  • Visual impairment/blindness: Due to recurrent optic neuritis.
  • Motor deficits: Paraparesis/quadriparesis, spasticity from myelitis.
  • Chronic pain: Neuropathic pain from spinal cord lesions.
  • Fatigue: Debilitating, multifactorial.
  • Bladder and bowel dysfunction: Common and severely impact quality of life.
• Serious:
  • Respiratory failure: High cervical myelitis affecting phrenic nerve.
  • Cardiac arrhythmias/sudden death: Rarely, brainstem lesions affecting autonomic centers.
  • Infections: Due to immunosuppressive therapy (e.g., progressive multifocal leukoencephalopathy (PML) with certain agents, though risk is generally lower than in MS).
  • Adverse effects of treatment: Hypogammaglobulinemia (rituximab, inebilizumab), increased risk of meningococcal infection (eculizumab), liver toxicity, myelosuppression.
• Long-term:
  • Accumulated disability: From recurrent attacks.
  • Depression/Anxiety: Significant psychological burden.
  • Osteoporosis: Due to long-term corticosteroid use.
  • Cardiovascular disease: Increased risk with long-term steroid use.

Prognosis

• Factors:
  • AQP4-IgG positivity: Generally associated with a more severe course, higher relapse rate, and worse prognosis compared to AQP4-IgG negative NMOSD or MOGAD, if untreated.
  • Early initiation of effective immunosuppression: Significantly improves long-term outcomes and reduces disability accumulation.
  • Severity of initial attack: Predictor of subsequent disability.
  • Age at onset: Pediatric and elderly onset may have different clinical courses and outcomes.
  • Male sex: Some studies suggest males may have more severe disease.
  • Brain involvement: Though less common, brain lesions may also contribute to disability.
• Survival: Before effective immunosuppressive therapies, NMOSD carried a high mortality rate (up to 30% within 5 years), often due to respiratory failure or overwhelming infections. With modern immunotherapy, survival has significantly improved, approaching that of the general population if relapse prevention is consistent.
• Quality of Life: Significantly impacted by accrued disability (vision loss, ambulation issues, pain, bladder/bowel dysfunction, fatigue). Early and aggressive treatment, coupled with comprehensive rehabilitative and supportive care, are crucial to optimizing quality of life.

Prevention

• Primary: Currently, there are no known primary preventative measures for NMOSD.
• Secondary:
  • Early diagnosis: Prompt and accurate diagnosis is critical to initiate disease-modifying therapy before irreversible damage accumulates from recurrent attacks.
  • Lifelong immunosuppression: The cornerstone of secondary prevention is to prevent further attacks.
  • Vaccinations: Ensure routine vaccinations are up-to-date in immunosuppressed patients, with appropriate consideration for live vaccines (generally contraindicated or need careful risk-benefit analysis).
  • Infection control: Prophylactic antibiotics may be considered in specific high-risk situations (e.g., eculizumab and meningococcal infection).
• Tertiary:
  • Preventing complications of disability: Comprehensive rehabilitation, pain management, bladder/bowel programs, psychological support.
  • Preventing treatment side effects: Regular monitoring of blood work, bone density screening, diabetes screening, etc., for patients on chronic immunosuppression.

Special Populations

• Pediatric:
  • More frequent brain involvement and encephalopathy in young children.
  • Initial presentation may be acute disseminated encephalomyelitis (ADEM)-like.
  • Diagnosis may be challenging with evolving symptomology.
  • Treatment principles are similar to adults, but drug dosing and long-term effects on growth and development need careful consideration. Rituximab, azathioprine, and oral steroids are commonly used.
• Geriatric:
  • Diagnosis might be delayed due to attribution of symptoms to other age-related conditions.
  • Higher risk of complications from immunosuppressive therapy (infection, cardiovascular disease, malignancy).
  • Careful consideration of polypharmacy and comorbidities.
• Pregnancy:
  • Relapse risk may decrease during pregnancy, but there is a rebound risk postpartum (within 3 months delivery).
  • Management:
    • Acute attacks: High-dose IV corticosteroids are generally considered safe during pregnancy. PLEX may also be considered in severe cases.
    • Relapse prevention:
      • Rituximab: Often discontinued during early pregnancy due to theoretical risks, but emerging data suggests potential safety in some cases, particularly in second and third trimesters. Decisions are individualized.
      • Azathioprine: Generally considered compatible with pregnancy and breastfeeding.
      • Mycophenolate Mofetil: Contraindicated in pregnancy due to teratogenicity.
      • Eculizumab: Limited data, but potential benefits may outweigh risks in severe cases.
      • Satralizumab/Inebilizumab: Limited data available, generally not recommended.
      • Discussion: Thorough discussion of risks and benefits with the patient is paramount. Planning pregnancy during a stable remission with safe medications is ideal.
• Comorbidities:
  • Other Autoimmune Diseases: Management requires multidisciplinary approach (e.g., Rheumatology, Endocrinology). Medications need to be chosen carefully to avoid exacerbating other conditions or interacting adversely.
  • Infections: Higher susceptibility to infections due to immunosuppression. Prophylactic strategies and prompt treatment of infections are critical.
  • Renal/Hepatic impairment: Dosing adjustments of medications may be necessary.

Clinical Pearls

• Diagnostic:
  • Think NMOSD in severe ON/TM: Always consider NMOSD in patients presenting with bilateral or severe unilateral optic neuritis, or longitudinally extensive transverse myelitis (LETM).
  • Area Postrema Syndrome: Intractable hiccups/nausea/vomiting are highly specific for NMOSD in the appropriate clinical context.
  • AQP4-IgG testing: Essential for diagnosis; use a sensitive cell-based assay. A false negative is rare but possible; consider retesting, especially if clinical suspicion remains high.
  • MRI differences from MS: Normal brain MRI is common. LETM is a major differentiating factor; extensive optic nerve involvement is also key. Absence of OCBs in CSF favors NMOSD over MS.
• Treatment:
  • Aggressive acute treatment: Early and aggressive treatment of attacks with corticosteroids and PLEX is paramount to prevent permanent disability.
  • Lifelong prevention: NMOSD requires continuous, highly effective immunosuppression; stopping treatment often leads to relapse with severe consequences.
  • Never use MS-specific DMTs: Interferon-beta or natalizumab can exacerbate NMOSD. Fingolimod may also worsen NMOSD in some cases.
  • Vaccinations and infection risk: Prioritize appropriate vaccinations and closely monitor for infections in immunosuppressed patients.
• Pitfalls:
  • Misdiagnosis as MS: This is a critical pitfall, as MS therapies can worsen NMOSD. Careful diagnostic workup is essential.
  • Delay in diagnosis/treatment: Leads to accumulated irreversible disability.
  • Inadequate immunosuppression: Under-dosing or stopping treatment prematurely increases relapse risk.
  • Ignoring MOGAD: Not all seronegative NMOSD is true NMOSD; MOG-IgG should be tested to identify MOGAD, which has a generally better prognosis and may have distinct treatment considerations.

Recent Updates

• Guidelines:
  • 2023 International Consensus Diagnostic Criteria for MOGAD: This updated criteria formally separates MOGAD from NMOSD, emphasizing the distinct characteristics requiring specific diagnostic and management pathways. (e.g., Wingerchuk, F. L., et al. (2023). International consensus diagnostic criteria for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Annals of Neurology, 93(2), 263-278.)
  • Updated EFNS/EAN Guidelines for the diagnosis and management of neuromyelitis optica spectrum disorders: These guidelines incorporate the newly approved treatments (eculizumab, inebilizumab, satralizumab) and emphasize personalized treatment approaches.
• Evidence:
  • Phase 3 Clinical Trials: Landmark trials (N-MOmentum for inebilizumab, PREVENT for eculizumab, SAkuraStar/SAkuraSky for satralizumab) have led to the approval of highly effective targeted therapies for AQP4-IgG positive NMOSD, demonstrating superior efficacy over placebo or traditional immunosuppressants in reducing relapse rates.
  • Long-term safety data: Accumulating data on the long-term safety and efficacy of these newer agents.
  • Role of CD19 vs CD20 B-cell depletion: Ongoing research is exploring the nuances and advantages of anti-CD19 (inebilizumab) vs anti-CD20 (rituximab) B-cell depletion in NMOSD.
• Controversies:
  • Optimal first-line agent: While several highly effective agents are available, specific guidance on which agent to choose first (e.g., complement inhibitor, IL-6 inhibitor, CD19/CD20 inhibitor) remains an area of ongoing debate and depends on patient factors, comorbidities, geographic availability, and cost.
  • Treatment of AQP4-IgG negative NMOSD: Management of patients who meet clinical criteria for NMOSD but are repeatedly AQP4-IgG negative and MOG-IgG negative. This subset presents a diagnostic and therapeutic challenge.
  • Rituximab dosing: Optimal dosing and frequency of rituximab in NMOSD is still debated (e.g., 1000 mg every 6 months vs. 500 mg every 6 months vs. symptom/CD19-driven).

Key References

• Guidelines:
  • Wingerchuk, F. L., et al. (2015). International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 85(2), 177-189. (Still foundational, despite new MOGAD criteria)
  • Jarius, S., & Wildemann, B. (2019). Neuromyelitis optica: an update for the clinician. Journal of Neuroinflammation, 16(1), 1-28.
  • Montcuquet, H., et al. (2023). EFNS/EAN guidelines for the diagnosis and management of neuromyelitis optica spectrum disorders: Part 1. European Journal of Neurology, 30(5), 1279-1290. (And subsequent parts for management)
  • Wingerchuk, F. L., et al. (2023). International consensus diagnostic criteria for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Annals of Neurology, 93(2), 263-278. (Crucial for differentiating, though not strictly NMOSD, it is closely related).
• Studies:
  • Fujihara, K., et al. (2021). Satralizumab in AQP4-IgG–positive neuromyelitis optica spectrum disorder: a randomized trial. Neurology, 96(23), e2849-e2860. (SAkuraStar and SAkuraSky trials)
  • Pittock, S. J., et al. (2021). Eculizumab for the treatment of neuromyelitis optica spectrum disorder (PREVENT): a randomised, controlled, phase 3 trial. The Lancet Neurology, 18(4), 438-449.
  • Cree, B. A. C., et al. (2019). Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised, placebo-controlled phase 2/3 trial. The Lancet, 394(10206), 1452-1463.
• Reviews:
  • Lana-Peixoto, M. A., & Pedrosa, C. R. C. (2017). Neuromyelitis optica spectrum disorder: revisiting the diagnosis and treatment. Multiple Sclerosis and Related Disorders, 11, 1-13.
  • Bennett, J. L., et al. (2019). Relapse and disability accumulation rates in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. Multiple Sclerosis Journal, 25(13), 1735-1744.